Details of the Drug

General Information of Drug (ID: DM5JVS3)

Drug Name

Isoniazid

Synonyms

Abdizide; Andrazide; Anidrasona; Antimicina; Antituberkulosum; Armacide; Armazid; Armazide; Atcotibine; Azuren; Bacillen; Bacillin; Cedin; Cemidon; Chemiazid; Chemidon; Continazine; Cortinazine; Cotinazin; Cotinizin; Defonin; Dibutin; Diforin; Dinacrin; Ditubin; Ebidene; Eralon; Ertuban; Eutizon; Evalon; Fetefu; Fimalene; HIA; Hidranizil; Hidrasonil; Hidrulta; Hidrun; Hycozid; Hydra; Hydrazid; Hydrazide; Hyozid; Hyzyd; INH; Idrazil; Inah; Inizid; Iscotin; Isidrina; Ismazide; Isobicina; Isocid; Isocidene; Isocotin; Isohydrazide; Isokin; Isolyn; Isonerit; Isonex; Isoniacid; Isoniazida; Isoniazide; Isoniazidum; Isonicazide; Isonicid; Isonico; Isonicotan; Isonicotil; Isonicotinhydrazid; Isonicotinohydrazide; Isonide; Isonidrin; Isonikazid; Isonilex; Isonin; Isonindon; Isonirit; Isoniton; Isonizida; Isonizide; Isotamine; Isotebe; Isotebezid; Isotinyl; Isozid; Isozide; Isozyd; LANIZID; Laniazid; Laniozid; Mybasan; Neoteben; Neoxin; Neumandin; Nevin; Niadrin; Nicazide; Nicetal; Nicizina; Niconyl; Nicotibina; Nicotibine; Nicotisan; Nicozide; Nidaton; Nidrazid; Nikozid; Niplen; Nitadon; Niteban; Nydrazid; Nyscozid; Pelazid; Percin; Phthisen; Pycazide; Pyreazid; Pyricidin; Pyridicin; Pyrizidin; Raumanon; Razide; Retozide; Rimicid; Rimifon; Rimiphone; Rimitsid; Robiselin; Robisellin; Roxifen; Sanohidrazina; Sauterazid; Sauterzid; Stanozide; Tebecid; Tebemid; Tebenic; Tebexin; Tebilon; Tebos; Teebaconin; Tekazin; Tibazide; Tibemid; Tibiazide; Tibinide; Tibison; Tibivis; Tibizide; Tibusan; Tisin; Tisiodrazida; Tizide; Tubazid; Tubazide; Tubeco; Tubecotubercid; Tubercid; Tuberian; Tubicon; Tubilysin; Tubizid; Tubomel; Tyvid; Unicocyde; Unicozyde; Vazadrine; Vederon; Zidafimia; Zinadon; Zonazide; Hid rasonil; Isoco tin; Isoniazid SA; Isozid e; Nidra zid; Rimif on; BP 5015; Bp 5 015; FSR 3; I0138; INHd20; L 1945; Nitebannsc 9659; Preparation 6424; RP 5015; AZT + Isoniazid; Cedin (Aerosol); Dow-Isoniazid; FRS-3; FSR-3; Ido-tebin; In-73; Inh-Burgthal; Isoniazid & EEP; Isoniazid & Propolis; Laniazid (TN); Neo-Tizide; Nydrazid (TN); RP-5015; TB-Phlogin; TB-Razide; TB-Vis; Usaf cb-2; I.A.I; RU-EF-Tb; RY-EF-Tb; I.A.I.

Indication

Disease Entry	ICD 11	Status	REF
Latent tuberculosis infection	N.A.	Approved	[1]
Pulmonary tuberculosis	1B10.Z	Approved	[1]
Tuberculosis	1B10-1B1Z	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antitubercular Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

137.14

Logarithm of the Partition Coefficient (xlogp)

-0.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 80% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 7.4 mL/min/kg [5]
Elimination: 7% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 0.5 - 1.6 hours [5]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 72.91702 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 1% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.82 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 153 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hepatotoxicity	Not Available	NAA20	OTJB0VA6	[7]
-----------

Chemical Identifiers

Formula: C6H7N3O
IUPAC Name: pyridine-4-carbohydrazide
Canonical SMILES: C1=CN=CC=C1C(=O)NN
InChI: InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
InChIKey: QRXWMOHMRWLFEY-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3767
ChEBI ID: CHEBI:6030
CAS Number: 54-85-3
DrugBank ID: DB00951
TTD ID: D09XQF
VARIDT ID: DR00422
INTEDE ID: DR0886
ACDINA ID: D00332

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Fatty acid synthetase I (Bact inhA)	TTVTX4N	INHA_MYCTU	Inhibitor	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[9]
Catalase-peroxidase (katG)	DEAGY5M	KATG_SYNE7	Substrate	[10]
Arylamine N-acetyltransferase (NAT)	DEXCQTM	A0A3P8LE58_TSUPA	Substrate	[11], [12]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[13]
5-aminolevulinate synthase, non-specific, mitochondrial (ALAS1)	OTQY6ZSF	HEM1_HUMAN	Gene/Protein Processing	[14]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Gene/Protein Processing	[15]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[16]
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Gene/Protein Processing	[17]
Alpha-fetoprotein (AFP)	OT9GG3ZI	FETA_HUMAN	Gene/Protein Processing	[13]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Gene/Protein Processing	[13]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[18]
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[19]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Isoniazid

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Rifampin	DMA8J1G	Minor	Increased risk of hepatotoxicity by the combination of Isoniazid and Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[20]
-----------

Coadministration of a Drug Treating the Disease Different from Isoniazid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[21]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Isoniazid caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Isoniazid caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Ivabradine	DM0L594	Moderate	Decreased metabolism of Isoniazid caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[23]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Isoniazid caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[24]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[25]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Isoniazid caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[26]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Isoniazid caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[27]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Isoniazid caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[28]
Roflumilast	DMPGHY8	Moderate	Decreased metabolism of Isoniazid caused by Roflumilast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[23]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Isoniazid caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[23]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Isoniazid and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[29]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Isoniazid caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[30]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Isoniazid caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Bosutinib	DMTI8YE	Moderate	Decreased metabolism of Isoniazid caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Isoniazid caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[31]
Doxercalciferol	DM6FG1P	Moderate	Increased metabolism of Isoniazid caused by Doxercalciferol mediated induction of CYP450 enzyme.	Chronic kidney disease [GB61]	[32]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Isoniazid caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[33]
Anisindione	DM2C48U	Moderate	Decreased metabolism of Isoniazid caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[34]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Isoniazid caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[23]
Levobupivacaine	DM783CH	Moderate	Decreased metabolism of Isoniazid caused by Levobupivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[23]
Halothane	DM80OZ5	Major	Increased risk of hepatotoxicity by the combination of Isoniazid and Halothane.	Corneal disease [9A76-9A78]	[35]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Isoniazid caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[28]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Isoniazid caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[23]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Isoniazid caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[36]
Escitalopram	DMFK9HG	Moderate	Decreased metabolism of Isoniazid caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[37]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Isoniazid caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[38]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Isoniazid caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Clonazepam	DMTO13J	Moderate	Decreased metabolism of Isoniazid caused by Clonazepam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Phenobarbital	DMXZOCG	Minor	Decreased metabolism of Isoniazid caused by Phenobarbital mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Cannabidiol.	Epileptic encephalopathy [8A62]	[23]
Tazemetostat	DMWP1BH	Moderate	Decreased metabolism of Isoniazid caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[41]
Solifenacin	DMG592Q	Moderate	Decreased metabolism of Isoniazid caused by Solifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[42]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Isoniazid caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[43]
Tolterodine	DMSHPW8	Moderate	Decreased metabolism of Isoniazid caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[44]
Itraconazole	DMCR1MV	Moderate	Increased metabolism of Isoniazid caused by Itraconazole mediated induction of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[21]
Ketoconazole	DMPZI3Q	Moderate	Increased metabolism of Isoniazid caused by Ketoconazole mediated induction of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[21]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Isoniazid caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[21]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Isoniazid caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[23]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[45]
MK-1439	DM215WE	Minor	Decreased metabolism of Isoniazid caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Isoniazid caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Lopinavir	DMITQS0	Minor	Decreased metabolism of Isoniazid caused by Lopinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Rilpivirine	DMJ0QOW	Moderate	Decreased metabolism of Isoniazid caused by Rilpivirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Abacavir	DMMN36E	Minor	Increased plasma concentrations of Isoniazid and Abacavir due to competitive inhibition of the same metabolic pathway.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Isoniazid caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Maraviroc	DMTL94F	Moderate	Decreased metabolism of Isoniazid caused by Maraviroc mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Isoniazid and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[51]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Isoniazid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[37]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Isoniazid and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[52]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Isoniazid caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[23]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Isoniazid caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[53]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Isoniazid caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[54]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Isoniazid caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[21]
Ramelteon	DM7IW9J	Moderate	Decreased metabolism of Isoniazid caused by Ramelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[55]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Isoniazid caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[56]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Isoniazid caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[57]
Quazepam	DMY4D87	Moderate	Decreased metabolism of Isoniazid caused by Quazepam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Estazolam	DMZGXUM	Moderate	Decreased metabolism of Isoniazid caused by Estazolam mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[39]
Alosetron	DML2A03	Moderate	Decreased metabolism of Isoniazid caused by Alosetron mediated inhibition of CYP450 enzyme.	Irritable bowel syndrome [DD91]	[58]
Naloxegol	DML0B41	Minor	Decreased metabolism of Isoniazid caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[59]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Isoniazid caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[23]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Isoniazid caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[21]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Isoniazid caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[60]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Isoniazid caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[61]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Isoniazid caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[62]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Isoniazid caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Isoniazid caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[64]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Isoniazid caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
Halofantrine	DMOMK1V	Major	Decreased metabolism of Isoniazid caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[65]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[66]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Idelalisib.	Mature B-cell leukaemia [2A82]	[67]
GDC-0199	DMH0QKA	Moderate	Decreased metabolism of Isoniazid caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[21]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Isoniazid caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[68]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Isoniazid caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[69]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Isoniazid caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[70]
Selumetinib	DMC7W6R	Moderate	Decreased metabolism of Isoniazid caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[71]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Isoniazid caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[72]
Dihydrotachysterol	DMFB97P	Moderate	Increased metabolism of Isoniazid caused by Dihydrotachysterol mediated induction of CYP450 enzyme.	Mineral deficiency [5B5K]	[32]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Isoniazid caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[73]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Isoniazid caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[74]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Isoniazid and Thalidomide.	Multiple myeloma [2A83]	[75]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Isoniazid caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[23]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Isoniazid caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[23]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Isoniazid caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[76]
Levomethadyl Acetate	DM06HG5	Major	Decreased metabolism of Isoniazid caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[77]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Isoniazid caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[78]
Safinamide	DM0YWJC	Moderate	Additive serotonergic effects by the combination of Isoniazid and Safinamide.	Parkinsonism [8A00]	[79]
Rasagiline	DM3WKQ4	Moderate	Decreased metabolism of Isoniazid caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[21]
Pimavanserin	DMR7IVC	Moderate	Decreased metabolism of Isoniazid caused by Pimavanserin mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[80]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Isoniazid caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[81]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Isoniazid caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[82]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Isoniazid caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[83]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Isoniazid caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[84]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Isoniazid caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[85]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Isoniazid caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[86]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Isoniazid and Leflunomide.	Rheumatoid arthritis [FA20]	[37]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Isoniazid caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[87]
Thiothixene	DMDINC4	Minor	Decreased metabolism of Isoniazid caused by Thiothixene.	Schizophrenia [6A20]	[88]
Asenapine	DMSQZE2	Moderate	Decreased metabolism of Isoniazid caused by Asenapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[89]
Pimozide	DMW83TP	Major	Decreased metabolism of Isoniazid caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[21]
LDE225	DMM9F25	Moderate	Decreased metabolism of Isoniazid caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[90]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Isoniazid caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Isoniazid and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[23]
Armodafinil	DMGB035	Minor	Decreased metabolism of Isoniazid caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
LEE011	DMMX75K	Moderate	Decreased metabolism of Isoniazid caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
-----------


⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Calcium sulfate dihydrate	E00315	24928	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Isoniazid 100 mg tablet	100 mg	Oral Tablet	Oral
Isoniazid 300 mg tablet	300 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Isoniazid FDA Label
2	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
9	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
10	Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro-drug isoniazid. FEBS Lett. 2015 Jan 2;589(1):131-7.
11	The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog. World J Microbiol Biotechnol. 2019 Oct 31;35(11):174.
12	Complete genome sequence of Tsukamurella paurometabola type strain (no. 33). Stand Genomic Sci. 2011 Jul 1;4(3):342-51.
13	Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
14	The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis. Toxicol Sci. 2019 Mar 1;168(1):209-224. doi: 10.1093/toxsci/kfy294.
15	Quercetin protected against isoniazide-induced HepG2 cell apoptosis by activating the SIRT1/ERK pathway. J Biochem Mol Toxicol. 2019 Sep;33(9):e22369. doi: 10.1002/jbt.22369. Epub 2019 Jul 23.
16	Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin. Chem Res Toxicol. 2015 Jan 20;28(1):51-8. doi: 10.1021/tx500285k. Epub 2014 Dec 9.
17	Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
18	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
19	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
20	Askgaard DS, Wilcke T, Dossing M "Hepatotoxicity caused by the combined action of isoniazid and rifampicin." Thorax 50 (1995): 213-4. [PMID: 7701468]
21	Cerner Multum, Inc. "Australian Product Information.".
22	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
23	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
25	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
26	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
27	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
28	Dal Negro R, Turco P, Trevisan F, De Conti F "Rifampicin-isoniazid and delayed elimination of theophylline: a case report." Int J Clin Pharmacol Res 8 (1988): 275-7. [PMID: 3182118]
29	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
30	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
31	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
32	Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
33	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34	Eade NR, McLeod PJ, MacLeod SM "Potentiation of bishydroxycoumarin in dogs by isoniazid and paminosalicylic acid." Am Rev Respir Dis 103 (1971): 792-9. [PMID: 4103778]
35	Bartelink AK, Lenders JW, van Herwaarden CL, et al "Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy." Tubercle 64 (1983): 125-8. [PMID: 6612792]
36	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
37	Canadian Pharmacists Association.
38	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
39	Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
40	Klotz U "The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications." Clin Pharmacokinet 46 (2007): 271-9. [PMID: 17375979]
41	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
42	Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
43	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
44	Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
45	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
46	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
47	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
48	Product Information. Ziagen (abacavir). Glaxo Wellcome, Research Triangle Pk, NC.
49	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
50	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
52	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
53	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
54	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55	Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
56	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
57	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
58	Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
59	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
60	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
61	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
62	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
64	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
65	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
66	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
67	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
68	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
69	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
71	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
72	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
73	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
74	Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
75	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
76	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
77	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
78	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
79	Product Information. Xadago (safinamide). US WorldMeds LLC, Louisville , KY.
80	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
81	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
82	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
83	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
84	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
85	Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
86	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
87	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
88	Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW "Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables." J Clin Psychopharmacol 11 (1991): 296-301. [PMID: 1765572]
89	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
90	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.